MicrobiologybioRxivPreprint
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant
A.-K. Reuschl, L. Thorne, L. Zuliani Alvarez…·N. J. Krogan
This study evaluates the efficacy of host-directed therapies against the B.1.1.7 SARS-CoV-2 variant and finds similar antiviral activity compared to early-lineage SARS-CoV-2.
DOI 10.1101/2021.01.24.427991